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A 24-year old man was referred to the Erasmus MC Bone Center because of an
asymptomatic increasing skull defect of the left parietal bone. The defect was first
noticed at the age of six, and gradually increased over the years. His medical history was
unremarkable, without any known trauma and a negative family history for bone diseases.
Laboratory tests showed a low vitamin D level without other abnormalities. Particularly,
there was no increase in markers of inflammation or bone turnover. CT-scans of the skull
showed an osteolytic region of the parietal skull bone, with a two-centimeter increase
in diameter over 9 years. Contrast enhanced MRI showed lymphangiogenic invasion,
which was compatible with our suspicion of Gorham-Stout disease. The patient was
referred to the neurosurgeon for treatment with a bone graft while considering additional
drug treatment. Gorham-Stout or vanishing bone disease is a rare entity characterized by
progressive osteolysis with lymphangiogenic bone invasion. Although already reported in
1838, currently the diagnosis and treatment of Gorham-Stout disease is still challenging.
The underlying pathophysiology is not clarified yet and several theories exist. The disease
usually affects persons younger than 40 years and the majority present with bone disease
of the maxillofacial region, the upper extremities or the torso. The clinical presentation
includes most frequently pain, swelling, and functional impairment of the affected region,
but the disease can also be asymptomatic. Laboratory investigations are usually normal,
and diagnosis is based upon imaging and sometimes pathology examination of affected
bone tissue. Treatment is experimental and there is no general consensus about the
best option due to lack of randomized controlled trials. Case reports showed patients
treated with bisphosphonates, interferon-alpha, anti-VEGF therapy, mTOR inhibitors, and
radiotherapy. There are some reports of surgery with prosthetic or bone grafts but no
long-term follow-up data exist. This paper describes a unique case of Gorham-Stout
disease of the parietal skull bone and discusses the current state of knowledge about
this rare bone disease.
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CASE PRESENTATION
A 24-year old man was referred to the Erasmus MC Bone Center
in Rotterdam, the Netherlands, because of a growing skull defect
of the left parietal bone. He had been analyzed in the referring
hospital because the defect became larger over time, but no
treatment was initiated. The defect was first noticed when he was
6 years old, and he nor his parents could remember any traumatic
incident. His medical history mentioned no relevant diseases and
he did not use any medication. He reached his target height
with no other skeletal deformities, had no other complaints and
was in good clinical condition. Family history was negative for
bone diseases.
Laboratory tests showed a low 25-hydroxy vitamin D level
(21 nmol/L, reference values 50–120 nmol/L), no increase in
inflammation markers [C-reactive protein (CRP), erythrocyte
sedimentation rate (ESR)], and normal bone turnover markers
in the form of alkaline phosphatase, procollagen type 1N
propeptide (P.1.N.P.), and beta isomer of C-terminal telopeptide
of type 1 collagen (beta-CTX) with only slightly increased
bone alkaline phosphatase (30.0 µg/L, reference value <20.1
µg/L). Also, serum levels of cytokines that may be involved
in the pathogenesis [interleukin-6 (IL-6), tumor necrosis factor
alpha (TNF-α), interleukin-1-beta (IL-1β)], were normal. The
results of the most relevant laboratory tests are shown in
Table 1. Laboratory test were performed according to standard
procedures. CT-scans of the referring hospital showed a region
of osteolysis of the diploë and outer table of the parietal bone,
with an intact inner table. The region size of the osteolytic
region slowly increased in size over the years. The first CT-
scan was performed at the age of 15 and showed a defect
with a maximum diameter of 38mm. One year later the defect
had increased to 41mm. CT-scans at the age of 22 and 24
showed an increase of the defect to a maximum diameter of
57 and 60mm, respectively. Figure 1 shows the most recently
performed CT-scan from the referring hospital with the defect
of 60mm. 3D-CT reconstructions were made to visualize the
extensiveness of the defect (Figure 2). Based on the clinical
manifestation and radiological findings the diagnosis Gorham-
Stout disease was suspected. To confirm this diagnosis, we
performed a contrast enhanced MRI-scan which showed an
enhancing zone of diploic vascularity at the edge of the osteolytic
region (Figure 3), characteristic of Gorham-Stout. We therefore
concluded that our patient suffered from Gorham-Stout disease
of the parietal bone. Additional bone scintigraphy showed no
other lesions. We were challenged by the decision to cover the
defect with or without removal of affected bone and whether
or not to start additional medical treatment. Due to the rarity
of the disease, lack of literature with respect to the underlying
pathophysiological mechanism and a standardized treatment
guideline, we performed a literature search to choose the best
clinical approach and also consulted experts in the field.
OVERVIEW OF THE LITERATURE ON
GORHAM-STOUT DISEASE
Gorham-Stout disease, also named vanishing bone disease,
phantom bone disease, or idiopathic massive osteolysis, is a
TABLE 1 | Results of the laboratory tests from the patient.
Laboratory
test
Serum value
(reference values)
Laboratory
test
Serum value
(reference values)
Calcium 2.51 (2.20–2.65 mmol/L) CRP <0.3 (<10 mg/L)
Phosphate 1.04 (0.80–1.40 mmol/L) ESR 2 (0–15 mm/h)
Albumin 53 (35–50 g/L) ALP 84 (<115 U/L)
25-OH-D 21 (50–120 mmol/L) Gamma-GT 23 (<55 U/L)
IL-6 <10 (<10 pg/mL) P.1.N.P. 93 (19.4–95.5 µg/L)
TNF-α <15 (<15 pg/mL) Beta-CTX 0.27 µg/L
IL-1β <10 (<10 pg/mL) Bone AF 30.0 (<20.1 µg/L)
IL-6, interleukin 6; TNF-α, tumor necrosis factor alpha; IL-1β, interleukin-1-beta; CRP,
C-reactive protein; ESR, erythrocyte sedimentation rate; ALP, alkaline phosphatase;
Gamma-GT, gamma glutamyltransferase; P.1.N.P., beta isomer of C-terminal telopeptide
of type 1 collagen; beta-CTX, beta isomer of C-terminal telopeptide of type 1 collagen.
FIGURE 1 | CT-scan of the patient showing the osteolytic skull defect of
60mm. (A) Axial plane, (B) coronal reconstruction showing irregular lobular
vessel shaped osteolysis at the medial side.
rare bone disorder characterized by progressive osteolysis with
lymphatic and vascular proliferation (1). The incidence is very
rare, with only a few hundred case reports described in literature
(1, 2). The disorder does not seem to exhibit a preference for
race, geographic area, or sex, although the disease might be
slightly more prevalent in males. No definite pattern of genetic
inheritance has been described, currently no cases with a family
history of the disease have been reported. It can be diagnosed at
every age, although most of the cases that have been described
occurred under the age of 40 years, with an average age at
diagnosis of 25 years (1, 3, 4).
Clinical Picture
Gorham-Stout disease most frequently involves the upper part
of the body. Most cases present with affected bones of the
maxillofacial region, vertebrae, ribs and the pelvic girdle, but it
can affect any part of the skeleton. In the majority of the cases the
disease is monostotic, involvement of multiple bones has been
described (3). There is no clear trigger in clinical practice that
causes the disease to occur. Sometimes the disease can occur after
a traumatic incident. After a trauma, the disease is confined to a
single location (5).
The clinical presentation and patient’s complaints are
dependent on the bone that is affected. Patients most frequently
present with local pain. This can be accompanied by functional
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FIGURE 2 | (A,C) Axial T1 MR images before contrast administration, (B,D)
post contrast T1 weighted MR images at the same level as (A,C). The main
area of osteolysis (A,B) is filled with non-enhancing soft-tissue. But there is
vascular shaped contrast enhancement in the diploë in (D) at the edge of the
osteolysis, this is the same area as mentioned in Figure 1B.
FIGURE 3 | 3D reconstruction of skull CT from multiple angles showing the
extensiveness and location of the defect of the left parietal bone.
impairment, muscle weakness or local edema. The disease can
also be completely asymptomatic, or may have a first presentation
with a spontaneous or traumatic fracture. Dyspnea can occur
due to chylothorax, a frequently seen complication in Gorham-
Stout disease of the bones in the thorax with a prevalence up
to 25%. Pleural effusion and chylothorax may develop when the
lymphoangiogenic invasion extends to the pleural cavity or the
thoracic duct (6).
The prognosis of Gorham-Stout disease is unpredictable
and varying, based on the extent, severity, and localization of
the disease. It is considered a benign disease and its natural
progression is characterized by spontaneous resolution. When
the disease has stabilized, the resorbed bone is not replaced
by new bone. Severe complications have been described and
can be life threatening. Besides the above described chylothorax
due to pleural involvement, rarely described complications
include hemangiomatous lesions of the skin, pericardial effusion,
osteomyelitis with septic shock, increased intracranial pressure,
meningitis, cerebrospinal fluid leakage, spinal cord involvement
and paraplegia by vertebral involvement (4, 7–9). In general,
visceral and spinal involvement are associated with a poor
prognosis (4).
Diagnosis
It can be a challenge to diagnose patients with Gorham-Stout
disease on the clinical, histological, and radiological features.
The disease can be misdiagnosed since it resembles other clinical
diseases that also present with pain of the musculoskeletal tract,
including rheumatoid arthritis, osteoarthritis, or osteomyelitis,
and other causes of osteolysis such as intraosseous malignancies,
granulomatous diseases, or central nervous system diseases such
as ameningioma or syringomyelia. In clinical practice, it is often a
diagnosis by exclusion, after ruling out inflammatory, infectious,
metabolic and neoplastic diseases (10). There is no standardized
guideline for diagnosis. Heffez et al. proposed an algorithm with
eight diagnostic criteria for Gorham-Stout disease. These are
based on clinical, radiological and histopathological findings and
are the following: (1) angiomatous tissue present in biopsy tissue,
(2) absence of cellular atypia, (3) minimal or no osteoblastic
response and absence of dystrophic calcifications, (4) evidence
of local progressive osseous resorption, (5) non-expansive,
non-ulcerative lesion, (6) absence of visceral involvement,
(7) osteolytic radiographic pattern, (8) negative hereditary,
metabolic, neoplastic, immunologic, and infectious etiology (11).
Laboratory tests are generally not helpful in the diagnosis of
Gorham-Stout disease since they are usually normal. There is
currently no specific biomarker that can be used to assess the
disease severity or that can be used in the follow-up to monitor
the response to therapy. Alkaline phosphatase may be increased
but is frequently normal (4, 10). Authors from a recent case
report on Gorham-Stout disease with vanishing of three ribs and
an osteolytic lesion of the left humerus bone suggest an initial set
of laboratory tests to use in the diagnostic phase, including bone
turnover markers. Since in this case, the bone turnover markers
P.1.N.P. and bone-specific alkaline phosphatase were increased,
the authors propose to use the bone turnover markers also for
follow-up (12). In reported studies, several factors weremeasured
in the blood of patients with Gorham-Stout disease (e.g., vascular
endothelial growth factors, IL-6, sRANKL, and osteoprotegerin).
IL-6 and VEGF-A were elevated in the blood of patients with
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Gorham-Stout disease (3), and in a recent study also the levels
of pyridinoline cross-linked carboxyterminal telopeptide of type
I (ICTP) and sclerostin (13). However, they can also be normal.
Conventional X-rays are not useful for early diagnosis of the
disease. Radiology findings at an early stage resemble patchy
osteoporosis and show radiolucent foci at intramedullary and
subcortical zones. If the disease progresses, bone deformities
develop with bone mass loss, atrophy, fracture, fragmentation,
and finally the image of vanishing bone (10, 14). Bone
scintigraphy mostly shows increased uptake in the blood
pool phase at the region of increased lymphatic and vascular
proliferation, and a region of decreased uptake at the osteolytic
region of vanished bone (4, 10, 15, 16). CT-scan is useful to
investigate the location and extent of the osteolytic bone, and can
sometimes show vessel shaped defects at the edge of osteolysis,
as in our case, but is mostly not characteristic for diagnosis.
MR imaging also shows the osteolysis and can clearly show the
vascular and/or lymphatic vessels within the bone which enhance
after contrast administration at the region of active osteolysis
(17). Finally, the diagnosis can be confirmed by histology from
a biopsy of the affected bone. In our patient, no biopsy of
the affected region was taken, as the MR characteristics of
an osteolytic region filled with non-enhancing soft-tissue and
vascular shaped contrast enhancement in the diploë at the edge
of the osteolysis, were very characteristic for the disease, and
there was no clinical or laboratory suspicion for an alternative
inflammatory, neoplastic, or infectious cause of the osteolysis.
Recently, a multidisciplinary guideline for the initial evaluation
of complicated lymphatic anomalies including Gorham-Stout
disease was published (18). Although based on expert opinion
consensus, authors present a diagnostic approach including
laboratory, radiological, and histological evaluation. They state
that the need for a histological biopsy should be discussed in a
multidisciplinary expert team after the clinical and radiological
evaluation. A possible complication of a biopsy is the oozing
of lymphatic fluid from the biopsy site, which may need lymph
drainage or can induce a chylothorax in the case of a biopsy of an
affected rib (18).
Pathogenesis
The first case of Gorham-Stout disease was already reported in
1838 and described a patient with a vanishing of the complete
humerus bone over 11 years (19). After more than a century,
in 1955, Gorham and Stout investigated the characteristic
histopathological findings of the massive osteolysis based on
8 cases. They discovered that the massive osteolysis was
accompanied by angiogenesis and lymphangiomatosis, with
proliferation of benign vascular structures and destruction of
osseous matrix. The lymphangiomatosis resulted in a zone of
hyperemia, which disrupts normal bone metabolism and shifts
the bone metabolism to favor osteoclastic activity. The destructed
bone tissue is replaced by fibrous tissue and no new bone
formation occurs (20). Further research with the development
of immunohistochemical markers of lymphatic endothelial cells
revealed that in Gorham-Stout disease lymphatic anomalies are
present in cortical and medullary parts of the bone, and that
these lymphatic vessels are normally not present in bone tissue
(3, 21). Although these findings were discovered decades ago,
currently the exact pathophysiologic mechanism is not clarified.
The proliferation of lymphatic vessels plays a central role in the
pathogenesis of the disease and several mechanisms appear to be
involved in the process of osteolysis.
An important role is attributed to the activation of
osteoclasts through the immune system. In Gorham-Stout
disease, an imbalance exists between osteoblasts and osteoclasts,
favoring osteoclast activity leading to bone resorption over
bone formation. Studies showed that in vitro, the osteoclast
differentiation is increased, while the function of the osteoblasts
is impaired with decreased bone mineralization ability (13).
Osteoclasts are activated by different cytokines which are secreted
by cells from the immune system. T-lymphocytes produce
cytokines such as interferon-gamma, tumor necrosis factor alpha,
prostaglandin E2, and interleukin 17, which induce the cytokine
receptor activator of nuclear factor kappa-B ligand (RANKL).
RANKL binds to the RANK receptor expressed on osteoclast
precursors, leading to differentiation and activation of the
osteoclasts (3). Furthermore, T-lymphocytes, but also leukocytes,
osteoblasts, and dendritic cells, produce IL-6 and consequently
activate mesenchymal stem cells in the bone marrow, stimulating
RANKL production (22, 23). As described above, in case reports
of Gorham-Stout disease the serum levels of IL-6 are sometimes
elevated (3, 13, 24). Whether there is a systemic immune
response, reflected by increased levels of cytokines in the serum
of some patients, or whether these cytokines act locally at the
defective bone, is currently not known.
Another role in the pathophysiological mechanism of
the disease is attributed to macrophages, that can induce
osteoclast activity and stimulate lymphangiogenesis through the
production of VEGF-A, -C, and -D (13, 22, 25). Furthermore,
they can inhibit osteoblast function by the production of TNF-
α. The growth factors VEGF-A and VEGF-C, but also platelet-
derived growth factor-BB, play a role in the invasion of lymphatic
vessels (26). These growth factors signal through the same
pathway which ends in the mammalian target of rapamycin
(mTor) (27–29). mTor is an important kinase in the progression
of the cell cycle and a key regulator of immune responses.
Furthermore, a role may be played by calcitonin, a hormone
which is produced by the parafollicular (C-cells) of the thyroid
gland and which has anti-osteoclastic properties. Interestingly,
a patient who has been reported with agenesis of these C-
Cells developed Gorham-Stout disease (30). Calcitonin binds to
the calcitonin receptor on osteoclasts, thereby inhibiting their
activity and thus inhibit osteoclastic bone resorption. This way,
lack of calcitonin can contribute to the osteolysis in Gorham-
Stout disease.
In the occurrence of Gorham-Stout disease after a trauma
or fracture, it is hypothesized that the pro-inflammatory
response after injury with cytokine secretion plays a role in the
development of the disease. For example, secreted interleukin-
1 (IL-1) induces angiogenesis and enhances the formation of
cartilaginous callus, which is also a histological finding in
Gorham-Stout disease.
However, to reveal the exact molecular triggers and
subsequent mechanisms that cause Gorham-Stout disease,
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more research is needed. It would be of most interest to reveal
the trigger or the origin of the lymphangiomatosis, finally leading
to osteolysis. Elucidating this may lead to a possible target for
therapy, which might allow early cessation of the cascade and
preventing bone destruction and loss.
Treatment
Since the underlying pathogenesis has not been clarified,
a targeted treatment strategy is lacking. Furthermore, no
prospective randomized controlled trials on treatment of
Gorham-Stout disease have been performed due to the rarity of
the disease. Several therapeutic options have been suggested to be
beneficial but results appear to be variable. Generally, treatment
consists of conservative therapy with medication, radiotherapy,
or invasive therapy with surgery. The choice for a certain
treatment is currently based on case reports from literature and
expert opinion.
The pharmacological treatment options target inhibition of
osteoclast activity, inhibition of angiogenesis or suppression
of the immune system. Pharmacological agents that have
been reported are bisphosphonates, interferon-a 2b,
mTor inhibitors, vitamin D, calcium, calcitonin, anti-
VEGF antibodies, bevacizumab, bleomycin, thalidomide,
somatostatin, androgens, propranolol, low-molecular-weight
heparin, and glucocorticosteroids (3). Patients have been
treated with monotherapy, but frequently a combination
of drugs has been used, such as bisphosphonates with
sirolimus (27) or bisphosphonates with interferon-a-2b
(31). Pharmacological treatment is also frequently combined
with surgery. Bisphosphonates are thought to be beneficial
through inhibition of osteoclast-mediated bone resorption,
and therefore counteract the osteolysis in attempt to stabilize
the disease process. Clinically, improvement of local pain and
inhibition of further osteolysis has been described (31, 32).
In the reported cases, bisphosphonates were mostly supplied
intravenously. Interferon-a 2b and thalidomide may be beneficial
through immunomodulatory and antiangiogenic effects. M-TOR
inhibitors such as sirolimus and everolimus inhibit the activation
of T-lymphocytes by inhibition of the intracellular signal
transduction. mTOR is an important kinase in the progression of
the cell cycle. The net result is immune suppression by inhibition
of lymphocytes and decreased lymphangiomatous invasion by
inhibition of lymphangiogenic growth factors (33, 34). The beta-
blocking agent propranolol has also been reported as therapeutic
option for Gorham-Stout disease, possibly through lowering
of VEGF-A levels (35). In their description of 186 reported
cases from literature with Gorham-Stout disease Dellinger
et al. present the clinical features including affected bones and
applied treatments in an overview table in the supplementary
material (3).
Radiation therapy may prevent progression of bone osteolysis
by inhibition of endothelial cell proliferation. It may prevent
disease progression or induce disease regression in 77–80% of
the Gorham-Stout disease cases. These percentages are based on
a literature analysis on 44 cases with Gorham-Stout disease in
which radiation therapy was used, and of results of 10 cases with
Gorham-Stout disease obtained from structured questionnaires
taken in radiation therapy settings, respectively. The treatment
seemed safe, with a mild early and late toxicity after a dose of
30–45Gy in total (36).
Surgical treatment is applied if patients complain about severe
pain and impaired function (7, 37, 38), if there is a fracture
or a high risk of fracture, or if complications occur such as
an increased intracranial pressure (39) or chylothorax (40) that
need surgical intervention. Surgery can consist of removal of the
affected bone tissue, with subsequent reconstruction by the use of
bone grafts, prostheses, or both.
Regarding the treatment of our case, lesions of the skull
have rarely been described in the parietal bone. More frequently
reported are skull-base defects, associated with cerebro-spinal
fluid leak and meningitis (3, 41). Furthermore, involvement
of the mandibulum is a frequently described location in the
skull (3). There are only two other reported case reports
of Gorham-Stout disease of the parietal bone. Amirjamshidi
et al. described a 62-year old man with a painful and tender
lesion of the right skull region, caused by a few centimeters
large lytic lesion of the parietal bone with MRI characteristics
of Gorham-Stout disease. Treatment with pharmacological
therapy including bisphosphonates and interferon-alpha−2b
did not result in pain relief. Subsequently, he underwent
craniotomy with removal of all affected bone and replacement
by a titanium plate. After this surgery, he was free of
complaints and follow-up after 1 year showed no recurrent
disease (42). Parihar et al. described a 35-year old female
patient with Gorham-Stout disease of the left parietal bone
of the skull, at the same location that was also painless.
The defect had a diameter of about 40mm. Treatment only
consisted of surgery with replacement of the affected bone using
cranioplasty with bone cement. Unfortunately, no follow-up data
is available (43).
CASE FOLLOW-UP
After the MRI-scan of the skull, we concluded that our patient
suffered from Gorham-Stout disease of the parietal bone. Since
his disease was progressive over the years, we attempt to
determine a proper treatment strategy with the goal to protect
the brain from mechanic injury locally at the defective zone,
and to prevent further osteolysis. But determining the most
adequate treatment approach is challenging since literature
is not conclusive on the precise treatment approach, reports
only a few patients with Gorham-Stout disease of the parietal
bone, and currently no guideline or widely accepted treatment
approach exists. We referred the patient to the neurosurgeon
for surgical treatment of the defect. Since only the inner table
is still present over a large area, there is an indication for
cranioplasty to protect the brain against mechanical injury. Based
on experience and literature from comparable bone defects of
the skull with other underlying causes, there are two possible
surgical approaches. First, to cover the defect with a custom
made 3D printed polyetheretherketone (PEEK) graft without
removing all of the affected bone. A possible complication
of this treatment is progression of the osteolysis around the
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graft and release of the graft with the potential necessity for
repeat surgery in the future. This approach is less invasive
and carries less risk than the second approach, which would
consist of the removal of all the affected remaining bone
including a margin of surrounding healthy bone tissue and
replacement with a custom made PEEK graft. This included
the skull over the superior sagittal sinus. Complications of
this operation are the risk of major bleeding from the venous
sinuses, venous sinus thrombosis causing cerebral infarction,
and -although unlikely- death. From literature, it cannot be
concluded whether removal of the affected bone with a margin
will prevent recurrence of disease and whether a more invasive
and riskier operation should be considered to cure the patient.
Importantly, no long-term follow-up data of either procedure
are available.
We decided to treat our patient with the first above
mentioned surgical approach in combination with an
intravenously supplied bisphosphonate. Currently, a custom
made PEEK-bone graft is being developed to cover the
defect. During surgery we will collect tissue for histological
confirmation of the diagnosis. After the surgery, we will
supply zoledronic acid five milligrams intravenously with
the intent to stop further osteolysis. Follow-up visits and
CT and MRI-scans on a regular basis will be used to
determine the duration of bisphosphonate treatment and
will explain whether the allocated therapy brings the osteolysis
to a halt.
CONCLUSION
We describe the case of a young man presenting with a 60mm
defect in the parietal bone of the skull due to Gorham-Stout
disease and discuss the challenging task to determine an
appropriate treatment strategy to prevent further osteolysis and
protect his brain from mechanical damage.
Gorham-Stout disease is a rare bone disease characterized
by progressive osteolysis with lymphatic and vascular
proliferation. Physicians should be aware of the existence
of this disease and once the diagnosis is suspected, referral
to a medical center dedicated to rare bone diseases is
recommended. Future research is needed since the exact
underlying mechanism is not revealed yet. Research
should focus on the triggers that initiate and maintain
the underlying pathophysiological mechanisms, to get
more insight directing toward the most appropriate
treatment strategy.
Our case is unique, since it is only the third patient
reported in literature with Gorham-Stout disease of the
parietal bone of the skull with the largest defect. Future
follow-up visits are needed to show whether further
osteolysis occurs.
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